Inogen, Inc (NASDAQ:INGN) shares hit a new 52-week high on Wednesday . The company traded as high as $98.78 and last traded at $98.78, with a volume of 101,440 shares trading hands. The stock had previously closed at $97.33.

A number of brokerages recently weighed in on INGN. Needham & Company LLC decreased their price target on shares of Inogen from $108.00 to $96.00 and set a “strong-buy” rating on the stock in a research note on Thursday, June 8th. BidaskClub lowered shares of Inogen from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Zacks Investment Research lowered shares of Inogen from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 8th. Finally, J P Morgan Chase & Co raised their price target on shares of Inogen to $102.00 and gave the company an “overweight” rating in a research note on Monday, June 26th. Three research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $91.60.

The firm has a 50-day moving average price of $94.64 and a 200-day moving average price of $86.04. The firm has a market cap of $2.09 billion, a price-to-earnings ratio of 87.49 and a beta of 1.02.

Inogen (NASDAQ:INGN) last announced its quarterly earnings results on Thursday, August 3rd. The medical technology company reported $0.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.28 by $0.10. Inogen had a net margin of 10.36% and a return on equity of 12.45%. The company had revenue of $64.10 million for the quarter, compared to the consensus estimate of $59.99 million. During the same quarter in the prior year, the firm earned $0.25 earnings per share. The company’s revenue for the quarter was up 17.4% compared to the same quarter last year. On average, equities research analysts predict that Inogen, Inc will post $1.21 earnings per share for the current fiscal year.

In other Inogen news, EVP Matt Scribner sold 2,500 shares of the company’s stock in a transaction dated Friday, June 16th. The shares were sold at an average price of $91.54, for a total value of $228,850.00. Following the sale, the executive vice president now owns 4,833 shares of the company’s stock, valued at $442,412.82. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Alison Bauerlein sold 6,667 shares of the company’s stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $92.64, for a total transaction of $617,630.88. Following the completion of the sale, the executive vice president now directly owns 15,000 shares in the company, valued at approximately $1,389,600. The disclosure for this sale can be found here. Insiders sold 57,467 shares of company stock worth $5,288,415 in the last ninety days. Insiders own 5.31% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Schroder Investment Management Group purchased a new stake in shares of Inogen in the second quarter valued at about $132,000. Ameritas Investment Partners Inc. purchased a new stake in shares of Inogen in the first quarter valued at about $109,000. Sei Investments Co. lifted its holdings in shares of Inogen by 38.1% in the second quarter. Sei Investments Co. now owns 1,606 shares of the medical technology company’s stock valued at $153,000 after purchasing an additional 443 shares in the last quarter. Victory Capital Management Inc. lifted its holdings in shares of Inogen by 36.1% in the first quarter. Victory Capital Management Inc. now owns 1,729 shares of the medical technology company’s stock valued at $134,000 after purchasing an additional 459 shares in the last quarter. Finally, State of Alaska Department of Revenue lifted its stake in shares of Inogen by 4.1% during the first quarter. State of Alaska Department of Revenue now owns 1,790 shares of the medical technology company’s stock valued at $138,000 after buying an additional 70 shares during the period.

WARNING: “Inogen, Inc (INGN) Reaches New 52-Week High at $98.78” was first posted by Daily Political and is owned by of Daily Political. If you are viewing this article on another publication, it was illegally stolen and republished in violation of US and international copyright and trademark laws. The original version of this article can be viewed at https://www.dailypolitical.com/2017/09/08/inogen-inc-ingn-reaches-new-52-week-high-at-98-78.html.

Inogen Company Profile

Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.